image credit: Freepik

Pfizer’s COVID jab sales swell again, with $36bn forecast for 2021

November 2, 2021

Fuelled by extensions to vaccination programmes to include children and booster shots, the BioNTech-partnered jab made nearly $13 billion in the third quarter, around $2 billion more than analyst consensus forecasts.

The tally accounted for more than half of Pfizer’s total revenues of $24.1 billion, which were up 134% on the same period of 2020, or 7% if Comirnaty’s sales are deducted.

Pfizer said it now expects to deliver 2.3 billion doses of Comirnaty this year and manufacture 3 billion, underscoring the dominance of Comirnaty against rival vaccines – at least in terms of dollar revenues.

Read More on Pharmaphorum